🇺🇸 FDA
Patent

US 7163934

Methods for treating delirium glucocorticoid receptor-specific antagonists

granted A61KA61K31/47A61K31/573

Quick answer

US patent 7163934 (Methods for treating delirium glucocorticoid receptor-specific antagonists) held by Corcept Therapeutics Incorporated expires Mon Jan 11 2027 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Corcept Therapeutics Incorporated
Grant date
Tue Jan 16 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 11 2027 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K31/47, A61K31/573